| Deciphering HER2 breast cancer disease: biological and clinical implications A Godoy-Ortiz, A Sanchez-Muñoz, MR Chica Parrado, M Álvarez, ... Frontiers in Oncology 9, 2019 | 76 | 2019 |
| Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study Cancers, 2021 | 36 | 2021 |
| Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients A Godoy-Ortiz, Y Plata, J Alcaide, A Galeote, B Pajares, E Saez, E Alba, ... Clinical and Translational Oncology 20, 922-927, 2018 | 30 | 2018 |
| Resistance to neoadjuvant treatment in breast cancer: clinicopathological and molecular predictors MR Chica-Parrado, A Godoy-Ortiz, B Jiménez, N Ribelles, I Barragan, ... Cancers 12 (8), 2012, 2020 | 19 | 2020 |
| Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity M Cobo, V Gutiérrez, R Villatoro, JM Trigo, I Ramos, O López, M Ruiz, ... Lung Cancer: Targets and Therapy, 57-66, 2017 | 15 | 2017 |
| Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative … N Ribelles, JM Jerez, P Rodriguez-Brazzarola, B Jimenez, ... European Journal of Cancer 144, 224-231, 2021 | 14 | 2021 |
| Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial A Oaknin, L Gladieff, J Martínez-García, G Villacampa, M Takekuma, ... The Lancet 403 (10421), 31-43, 2024 | 13 | 2024 |
| Unveiling the potential of liquid biopsy in HER2-positive breast cancer management A Godoy-Ortiz, A Alba-Bernal, J Pascual, I Comino-Méndez, E Alba Cancers 14 (3), 587, 2022 | 9 | 2022 |
| VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum … A Oaknin, L Gladieff, J Martinez-Garcia, G Villacampa, M Takekuma, ... Annals of Oncology 34 (12), 1198-1200, 2023 | 6 | 2023 |
| Afatinib en pacientes con carcinoma escamoso de pulmón: contexto actual y opción de un tratamiento oral M Cobo, V Gutiérrez, L Rodelo, O López, M Ruiz, A Godoy Medicina Clínica 146, 25-29, 2016 | 5 | 2016 |
| Development of a novel NGS methodology for ultrasensitive circulating tumor DNA detection as a tool for early-stage breast cancer diagnosis B Jiménez-Rodríguez, A Alba-Bernal, E López-López, ME Quirós-Ortega, ... International Journal of Molecular Sciences 24 (1), 146, 2022 | 4 | 2022 |
| Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. Front AG Ortiz, AS Muñoz, MRC Parrado, MÁ Pérez, NR Entrena, ... Oncol 9, 1124, 2019 | 4 | 2019 |
| Rapid diagnostic tests for dengue would reduce hospitalizations, healthcare costs and antibiotic prescriptions in Spain: A cost-effectiveness analysis D Camprubí-Ferrer, F Ramponi, L Balerdi-Sarasola, A Godoy, E Sicuri, ... Enfermedades Infecciosas y Microbiología Clínica 42 (1), 30-33, 2024 | 3 | 2024 |
| Afatinib in patients with squamous cell carcinoma of the lung: Current context and the option of oral treatment M Cobo, V Gutiérrez, L Rodelo, O López, M Ruiz, A Godoy Medicina Clinica 146, 25-29, 2016 | 2 | 2016 |
| Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients V Sánchez-Martín, E López-López, D Reguero-Paredes, A Godoy-Ortiz, ... Clinica Chimica Acta 552, 117673, 2024 | 1 | 2024 |
| Open-label, phase 2, randomized controlled multicenter study comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in participants with … X Zeng, J Belotte, B Felicetti, A Baines, A Youssefagha, L Rojas-Espaillat, ... Gynecologic Oncology 176, S159-S160, 2023 | 1 | 2023 |
| Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC) E Ciruelos, C Saura, X González-Farré, JS Bofill, M Vidal, I Blancas, ... Cancer Research 82 (4_Supplement), OT2-27-01-OT2-27-01, 2022 | 1 | 2022 |
| Predicting the risk of VISIT emergency department (ED) in lung cancer patients using machine learning. P Rodriguez-Brazzarola, N Ribelles, JM Jerez, J Trigo, M Cobo, ... Journal of Clinical Oncology 38 (15_suppl), 2042-2042, 2020 | 1 | 2020 |
| Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV … J Belotte, B Felicetti, AJ Baines, A YoussefAgha, L Rojas-Espaillat, ... Trials 25 (1), 301, 2024 | | 2024 |
| Abstract LBO1-02: Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer … L Gianni, E Munzone, M Mansutti, G Bianchini, Y Izarzuzaga, ... Cancer Research 84 (9_Supplement), LBO1-02-LBO1-02, 2024 | | 2024 |
